NA Proactive news snapshot: Cloud DX, New Oroperu Resources, Todos Medical, Kainantu Resources, CleanSpark UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Cloud DX Inc (CVE:CDX) said Brad Miller, a director of the company (formerly Roosevelt Capital Group), as a result of the previously announced qualifying transaction and related transactions, had acquired beneficial ownership and control over 7,307,337 shares and 100,000 share purchase warrants issued to B and M Miller Equity Holdings Inc - an entity controlled by Mr Miller. The shares and warrants were issued in exchange for the securities of Cloud Canada held by B&M prior to completion of the qualifying transaction. As a result of the qualifying transaction, B&M has ownership and control over 10.13% of the shares on a non-diluted basis and around 10.28% of the shares on a partially diluted basis assuming t
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE)
KULR Technology Group Inc. (OTCQB: KULR) (the Company or KULR ), a leading developer of next-generation thermal management technologies, today announced Antonio Martinez will be the new Vice President of Operations. Mr. Martinez will be responsible for managing day-to-day operations of the Company’s manufacturing department as well as supporting strategic growth goals.
Mr. Martinez joins KULR with over 37 years of leadership and worldwide manufacturing experience in Electronics Manufacturing and Operations. He spent most of his career at Pulse Electronics Corporation in the electronics manufacturing services industry. Most recently he served as Principal Program Manager of Jabil (NYSE: JBL) since 2015, managing business operations spanning Quality Assurance Readiness, Large Production Line Transfers, Project Management, Process Improvement with Increased Productivity, and Customer Qualification Support.
By Molly Burgess2021-04-20T16:28:00+01:00
Global natural and organic foods retailer Whole Foods Market will utilise Honeywell’s Solstice® N40 (R-448A) lower global-warming-potential (GWP) refrigerants in its US store.
The installation is planned for more than 100 Whole Foods stores as part of an effort to reduce refrigerant emissions under the US Environmental Protection Agency’s GreenChill programme.
Based on hydrofluoroolefin (HFO) technology, Solstice N40 offers a GWP that is approximately 68% lower than legacy hydrofluorocarbon (HFC) refrigerants like R-404A.
When using Solstice N40, refrigeration systems also consume less energy than their counterparts that cool using HFCs. In US and European supermarket trials, in comparison to R-404A, Solstice N40 demonstrated an average of between 5 to 15% lower energy consumption in refrigeration applications.
NA Proactive news snapshot: The Good Shroom Co, Golden Minerals, Codebase Ventures, Vicinity Motor …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
The Good Shroom Co Inc. (CVE:MUSH), previously Cluny Capital Corp, (CVE:CLN.H), a Toronto Venture Exchange (TSX) capital pool company, has announced the completion of its qualifying transaction, which involved the amalgamation of Teonan Biomedical Inc. with the company s wholly-owned subsidiary, as part of a three-cornered amalgamation between the parties. Immediately prior to the transaction, the company was continued under the Canada Business Corporations Act, its outstanding common shares were consolidated on a 3 for 1 basis and, the company changed its name to The Good Shroom Co Inc. (Les Bons Champignons Inc.).
NA Proactive news snapshot: Todos Medical, Kainantu Resources, CleanSpark, Arcadia Biosciences UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Todos Medical Ltd (OTCQB:TOMDF) has announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 clinical trial of antiviral Tollovir for the treatment of hospitalized coronavirus (COVID-19) patients. The trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel, and will evaluate the safety and efficacy of Tollovir, the company said. Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos and NLC Pharma. It is among 3CL protease inhibitors that are targeted as desirable candidates for the development of antiviral therapies against SARS-CoV-2, the virus that causes the COVID-19 disease.